FDA Fast Tracks Certa Therapeutics’ FT011 for Systemic Sclerosis
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Certa Therapeutics’ investigational therapy FT011 for the treatment of systemic sclerosis. FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs. It targets a GPCR receptor, GPCR68, with an extensive body of data demonstrating promising efficacy […]